"We saw simulated benefits for both MIs and all-cause mortality, with a greater benefit for all-cause mortality," said Holman, emeritus professor of diabetic medicine, Radcliffe Department of Medicine, University of Oxford, UK. And the "introduction of new glucose-lowering agents [following the UKPDS trial], especially those that do not induce hypoglycemia or weight gain, has made it easier to take advantage of this' legacy' effect," said Holman.